The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Lovells has strengthened its life sciences group with the addition of former Merck Sharp & Dohme legal director Marc Dalby.
At Merck Sharp & Dohme, which is a client of the firm and the UK subsidiary of Merck & Co, Dalby was company secretary in addition to legal director. He has not yet been replaced.
Dalby joined the City firm last Tuesday (8 May) as a consultant in the life sciences team, as first revealed on www.thelawyer. com (8 May). He focuses on the regulation of pharmaceutical promotion, competition law, product liability and data exclusivity.
Dalby is a longstanding member of the legal affairs committee of the Association of the British Pharmaceutical Industry (ABPI) and has sat on a number of ABPI working groups and subcommittees.
He was called to the bar in 1986 and went on to practise at 5 King's Bench Walk. He has also held legal positions at Lloyd's of London and Napp Pharmaceuticals.